Last reviewed · How we verify

NCT06798402

Ciprofloxacin Intralesional Injection for the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stibogluconate

Recruiting now Phase 2 Last updated 30 September 2025
What this trial tests

Phase 2 trial testing Ciprofloxacin (BAYO9867) in Cutaneous Leishmaniasis in 80 participants. Currently enrolling.

Timeline
7 February 2025
Primary endpoint
1 November 2025
1 November 2025

Quick facts

Lead sponsorAl-Mustafa University College
PhasePhase 2
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment80
Start date7 February 2025
Primary completion1 November 2025
Estimated completion1 November 2025
Sites1 location across Iraq

Drugs / interventions tested

Conditions studied

Sponsor

Al-Mustafa University College

Who can join

Adults 18 to 80, any sex, with Cutaneous Leishmaniasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Aim of the trial to evaluate the effectiveness of intralesional ciprofloxacin 0.2% solution as a local injection in treating cutaneous leishmaniasis and compare its effect with intralesional sodium stibogluconate (SSG) 10% intravenous solution in cutaneous leishmaniasis as a local injection. In a randomized parallel groups clinical trial, patients were divided into two groups based on therapeutic regimen: 1) intralesional sodium stibogluconate weekly injection and 2) intralesional ciprofloxacin injection. Each lesion was considered a case in the final analysis. Each lesion will be followed up for 90 days (censor endpoint) or until the lesions are cured.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cutaneous Leishmaniasis

Currently open trials in the same condition.

Other Al-Mustafa University College trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06798402.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing